Viscous medical product for injections, containing ethanol and fat-soluble, impenetrable connection for x-ray radiation
SUBSTANCE: invention is used for treatment venous malformations, administered by means of injections. The declared preparation contains ethanol with the degree of cleanliness from 70 to 99 % which is necessary for the effect causing sclerosis, a difficult ethyl ester of the iodated fat acid, and in addition contains ethyl cellulose or dextrin, providing viscosity of the solution from 10 to 700 cPz, for the preparation of gel with the emboli effect.
EFFECT: declared drug provides reliable application at all stages of course of the treatment and ability to formation of a selective steady sclerosis, also the invention provides biological compatibility, high ability to densifying, formation of biodegrading derivatives, an exception of local or system toxic effects.
6 cl, 1 tbl, 2 ex
The present invention relates to a viscous pharmaceutical preparation for injection containing ethanol and fat-soluble, impervious to x-rays connection. It applies in particular, but not exclusively, in the treatment of venous malformations, such as venous angiomas.
Typically, venous malformation characterized by swelling bluish color, which is soft, compressible, swollen at the bottom or when pressed.
They can be more or less pronounced volume and placed in hard to reach or the affected areas in which surgical resection is sometimes difficult or even impossible.
For the treatment of such zones was proposed pure ethanol for percutaneous introduction the purpose of education sclerosis malformations. Its effectiveness is not in doubt, but its use is associated with a significant risk for the following reasons:
defiant sclerosis substance is a liquid, and its spread beyond the pathological zone is controlled only partially carefully check the correct position of the injection needle in the area of malformations in the preliminary series angiography;
he is not radiopaque, and areas with the calling sclerosis substance not controlled or during injection or after it;
- described, although rare, is, but severe cases cardiac and General toxicity caused directly by the injection of ethanol in zone venous malformations.
For the safe and effective use of pure ethanol proposed a mixture of ethanol and connections to obtain a viscous product, such as ethylcellulose, dextrin or one of their derivatives. This mixture forms a gel with the following two main advantages:
- he is able to be injected with a needle into the area of venous malformations, and its spread into unwanted areas are severely limited compared to the pure ethanol
- due to their physical properties, the gel remains near the injection zone and creates a very high-sclerotic effect. The amount needed to obtain the same result, dramatically reduced compared to pure ethanol at reducing the risk of General toxicity.
However, this gel has two significant drawbacks:
he is not radiopaque,
- there is a direct occulation calling sclerosis mixture (ethanol/ethyl cellulose) in contact with water-soluble contrast agents commonly used in vascular radiology, impedes the movement of the gel in the needle during injection and precluding its use in the catheter.
The subject of the invention is to eliminate these drawbacks is s.
Therefore, the proposed medicinal preparation for injection containing ethanol and at least one fat-soluble compound of at least partial proof for x-rays.
According to the invention the specified drug differs in that it additionally contains soluble in ethanol compound whose viscosity in the solution is from 10 to 700 centipoise, preferably from 90 to 350 centipoise, at 25°C., to obtain a gel with the effect of embolism and that the degree of purity of the ethanol is from 70 to 99% by volume, preferably from 90 to 99% by volume, to obtain the caller sclerosis effect.
It should be stated that centipoise (CP) means a unit of dynamic viscosity equal to 10-3Pascal second (PA·s).
Needless to say that the specified connection with a viscosity in solution of ethanol from 10 to 700 centipoise, preferably from 90 to 350 centipoise, at 25°C, may contain at least one fat-soluble compound, which is at least partially impermeable to x-rays. These compounds are inert with respect to each other.
In the preparation according to the invention can be administered active substances.
More specifically, this preparation may consist of emulsion, which is in the state between the viscous phase, containing, at least, ethanol, and ironist oimoi phase, containing at least the specified fat-soluble compound, which is at least partially impermeable to x-rays.
The preparation according to the invention may contain from 10 to 50 volume% of the specified fat-soluble compounds, which are at least partially impermeable to x-rays.
While it is preferable to have in mind that the more emulsion contains fine particles, the more uniform will be the mixture and the more effective will be monitoring the passage of the mixture during injection.
Mentioned emulsion can be prepared by introduction of this fat-soluble compound, which is at least partially impermeable to x-ray radiation, or at the end of the preparation of the drug, or immediately before its introduction.
Fat-soluble compound, which is at least partially impermeable to x-ray radiation, may represent a non-metallic connection.
These non-metallic connection can serve ester, halogenated fatty acids, such as ethyl esters of iodized fatty acids.
Preferably, in the case of finding venous malformations near the skin, which are often treated mainly for aesthetic reasons, nonmetallic was sedimentational prevention of skin color in black color, such that it acquires when using metal compounds.
The specified connection, which has a solution viscosity of from 10 to 700 centipoise, preferably from 90 to 350 centipoise, can be selected in order to achieve the following properties:
biological compatibility in connection with the use of the drug for injection,
- a relatively high ability to thickening for increasing the viscosity of the mixture even at low content
- education biodegrading derived in situ, eliminating the need for surgical intervention in the treatment area,
- solubility in cold condition in ethanol to prepare a homogeneous preparation,
- minimize, even complete elimination of local and/or systemic toxic effects to reduce tolerability of the drug, and, if necessary, the possibility of preparation in powder form, not liquid to eliminate the need to dilute ethanol.
The specified connection with a viscosity of from 10 to 700 centipoise, preferably from 90 to 350 centipoise, at 25°C can be ethylcellulose.
Ethylcellulose can be contained in an amount of from 0.5 to 30 wt.%, preferably from 5 to 18 wt.%, the total weight of the preparation.
Therefore, the preparation according to the invention meets all the basic criteria, which are reliable use in all one hundred is the second course of treatment and the ability to form selective sustainable sclerosis.
Below as a non-limiting example describes a variant implementation of the invention with reference to the attached drawings, which represent:
figure 1 - measurement of viscosity in centipoise depending on the concentration in wt.% ethyl cellulose by weight;
figure 2 - measurement of viscosity in centipoise depending on the temperature in degrees Celsius.
There are several drugs with different content of ethyl cellulose (Aqualon 100 NF®, Hercules), received its dissolution in number respectively 0,15; 0.45 and 0.75 g in 15 ml of ethanol with purity of from 70 to 99 volume%, preferably 95% by volume (d=0,8), which is 1,22; 3,61 and 5,88% wt. the total weight of the preparation. Was selected drug with a maximum concentration of ethyl cellulose. When dosing forty tanks at a ratio of 205 ml of 95% alcohol (by volume) and of 10.25 g of ethyl cellulose loss was 2.5%. In General, the content of ethyl cellulose ranged from 5 to 18 wt.%, preferably 5,88 wt.%, the total weight of the preparation.
In accordance with the Technological recommendations (1998) the drug is prepared in three stages: preparation of the gel, sterile packaging and sterilization of the product at the final conditioning. Initially indifferent substance (ethylcellulose) was mixed with ethanol in a sterile flask with a glass stopper with Nagravision magnetic shaking under reflux until complete dissolution. The whole complex continued to shake with the use of a dephlegmator for fifteen minutes, then shook to cool to re-condensation of the alcohol in the flask. Re-conditioning was conducted in a laminar box under a horizontal laminar flow when filling sterile sealable containers with a capacity of 5 ml (biological unit 42065). Finally, as recommended in the European Pharmacopoeia, the containers were sterilized in the autoclave with saturated steam at 121°C for twenty minutes.
The last stage of preparation of the drug was fat-soluble additive that causes the opacity of a substance, such as a complex ethyl ester of iodinated fatty acids (Laboratory coat of Arms, France), in varying amounts to obtain the necessary opacity, for example, from 10 to 50% by volume of the total volume.
Because this substance (fat-soluble phase) is not mixed with a mixture of ethanol/ethylcellulose (viscous phase), through the merger of the two phases formed suspension, the particle size of which depends on produced by mixing. It should be noted that the finer the particles, the more uniform injectable mixture and the more effective control over the injection.
This additive may be, for example, in the syringe before injection.
However, because this substance I which is inert and used in small quantities, it does not significantly affect the results of the control described below and carried out in respect of the drug to its Supplement.
Ongoing control measures
Compliance testing of the drug was carried out through a sterile test, as well as by chemical and physical control measures.
According to the recommendations of the European Pharmacopoeia possible presence of pathogens was determined by seeding 4 ml 250 ml broth of soy tryticase for aerobic microbes, thioglycolate for aerobic microbes and Sabouraud's yeast. The results of the sterility test confirmed the absence of pathogens in the product.
The alcohol content was determined after dilution and injection internal standard, propanol-1, by gas chromatography using flame ionization. The separation was carried out in the column of Porapak Q (80-100 mesh (cell), height: 3 m) using nitrogen as the gas vector (1,2 bar) on the device Delsi DN200. During the titration of alcohol received indicator 802 G.-1.
Specific titration additives for viscosity were not conducted, however, the concentration was determined by the method of dry residue, reception, namely, that the ethanol is evaporated in a thermostatted cuvette at a temperature of 110°C to obtain a constant weight of the sample. Method of dry residue allows you the option of submitting a correlation calculation of the concentration of ethyl cellulose concentration, measured experimentally and formed 5,88% by volume of the total sample weight.
The viscosity of the preparation was measured using a capillary viscosimeter the Boma (Prolabo). There have been several series of measurements at different temperatures and different concentrations of thickener of the drug. The viscosity measurements showed that at constant temperature the viscosity of the drug increases exponentially with the content of ethyl cellulose (figure 1). Simultaneously, the viscosity decreases exponentially with increasing temperature (figure 2).
Finally, a study was conducted to determine the physicochemical stability through the analysis of the phase changes of the parameters characterizing the drug, i.e. its viscosity and content of ethanol and adding the viscosity of the substance. The measurement was repeated through the day (J1), eight days (J8) and thirty days (J30).
The results are shown in table 1. The change factors of less than 3%, confirmed the stability of the mixture for up to 30 days, which allows to define the minimum shelf-life of the drug.
|The correlation of physico-chemical parameters of the drug from the storage duration|
|Duration||ethanol, G.-1||Vsamplesml||Psamplesg||dsamples, GML-1||The dry residue, g||The ratio of dry residue/Psamples, %||Viscosity, centipoise|
|The rate of change||2,665||-||2,751||2,489||2,458||the 1.265||2,976|
1. Drug for the treatment of venous malformations, administered by injection, containing ethanol and at least one complex ethyl ester of iodinated fatty acid, characterized in that it further comprises ethylcellulose or dextrin, providing the viscosity of the solution is from 10 to 700 centipoise, preferably from 90 to 350 centipoise, at 25°C., to obtain a gel with the effect of embolism, and that ethanol has a purity of from 70 to 99%, preferably from 90 to 99%, necessary to obtain the caller sclerosis effect.
2. The drug pop, characterized in that ethylcellulose, dextrin, ethanol and at least one complex ethyl ester of iodinated fatty acids are inert with respect to each other.
3. The preparation according to claim 1, characterized in that it comprises emulsion-based viscous phase containing ethanol, and at least one complex ethyl ester of iodinated fatty acids.
4. The preparation according to claim 1, characterized in that it contains about 10-50 vol.% complex ethyl ester of iodinated fatty acids.
5. The preparation according to claim 1, characterized in that ethylcellulose or dextrin have the following properties:
sufficiently high thickening ability to increase the viscosity of the mixture even at low contents,
the formation of derivatives with biological degradation in situ,
solubility in ethanol in a cold state,
minimize local and/or systemic toxic effects.
6. The preparation according to claim 1, characterized in that ethylcellulose or dextrin have a powder form.
SUBSTANCE: invention refers to new compounds of formula (I) where X is carboxylic acid, carboxylates, carboxylic anhydride, diglyceride, triglyceride, phospholipid, or carboxamides, or to any their pharmaceutically acceptable salt. The invention particularly refers to (4Z, 7Z, 10Z, 13Z, 16Z, 19Z)-ethyl 2-ethyldocosa-4,7,10,13,16,19-hexanoate. The invention also refers to a food lipid composition and to a composition for diabetes, for reducing insulin, blood glucose, plasma triglyceride, for dislipidemia, for reducing blood cholesterol, body weight and for peripheral insulin resistance, including such compounds. Besides, the invention refers to methods for treating and/or preventing diabetes, dislipidemia, peripheral insulin resistance, body weight reduction and/or weight gain prevention, insulin, blood cholesterol, blood glucose and/or plasma triglyceride reduction.
EFFECT: higher clinical effectiveness.
61 cl, 4 tbl, 16 dwg, 5 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds of general formula
where R1 represents CH3; R2 represents halogeno or CN; R3 represents H or CH3; R4 represents H or CH3; n represents 0, 1 or 2; and to their pharmaceutically acceptable salts. Also, the invention refers to a pharmaceutical composition and to application of the compounds of formula (I) in preparing a drug exhibiting antagonist activity in relation to CX3CR1 receptor.
EFFECT: provided the compounds of formula (I) as CX3CR1 receptor antagonists.
20 cl, 1 tbl, 3 dwg, 10 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: present inventions refers to a new crystalline form of tetomilast hydrate of the X-ray powder diffraction spectrum having characteristic peaks at the angle 20=10.6°, 12.9°, 21.1°, 22.3° and 25.0°, to a new crystalline form of anhydrous tetomilast type C of the X-ray powder diffraction spectrum having characteristic peaks at the angle 2θ=4.2°, 8.2°, 12.0°, 16.4°, 24.7° and 25.9°, to a new crystalline form of acetonitrile tetomilast solvate of the X-ray powder diffraction spectrum having characteristic peaks at the angle 2θ=3.6°, 7.1°, 10.6°, 14.2° and 24.8°, to based pharmaceutical compositions and to methods for preparing.
EFFECT: new crystalline forms shows useful processing characteristics with relation to preparing pharmaceutical drugs of them.
13 cl, 14 dwg, 8 ex
SUBSTANCE: present invention is related to new quinolone derivatives of general formula (I) where R1: C3-6cycloalkyl or lower alkylene C3-6cycloalkyl, R2: -H or halogen, R3: -H, halogen, -OR0 or -O-(lower alkylene)-phenyl, R0: are the same or different from each other, and each represents -H or lower alkyl, R4: lower alkyl, halogen(lower alkyl), lower alkyleneC3-6cycloalkyl, C3-7cycloalkyl or a heterocyclic group, where cycloalkyl and the heterocyclic group specified in R4 can be respectively substituted, R5: -NO2, -CN, -L-Ra, -C(O)R0, -O-Rb, -N(R6)2, lower alkylene-N(R6)(Rc), -N(R6)C(O)-Rd, lower alkylene-N(R6)C(O)-Rd, lower alkylene-N(R0)C(O)O-(lower alkyl), -N(R0)C(O)N(R0)-Re, lower alkylene-N(R0)C(O)N(R0)-Re, -N(R0)S(O)2N(R0)C(O)-Rd, -CH=NOH, C3-6cycloalkyl, (2,4-dioxo-1,3-thiazolidin-5-yliden)methyl or (4-oxo-2-tioxo-1,3-thiazolidin-5-yliden)methyl where cycloalkyl specified in R5 can be respectively substituted, R6: H, lower alkyl, lower alkylene-CO2R0 or lower alkylene-P(O)((OPp)2, where lower alkylene specified in R6 can be substituted, L: lower alkylene or lower alkenylene which can be respectively substituted, Ra: -OR0, -O-(lower alkylene)-phenyl, -O-(lower alkylene)-CO2R0, -CO2R0, -C(O)NHOH, -C(O)N(R6)2, -C(O)N(R0)-S(O)2-(lower alkyl), -C(O)N(R0)-S(O)2-phenyl, -C(O)N(R0)-S(O)2-(heterocyclic group), -NH2OH, -OC(O)R0, -OC(O)-(halogen(lower alkyl)), -P(O)(ORp)2, phenyl or the heterocyclic group where phenyl or the heterocyclic group specified in Ra can be substituted, Rp: R0, lower alkylene-OC(O)-(lower alkyl), lower alkylene-OC(O)-C3-6cycloalkyl, lower alkylene-OC(O)O-(lower alkyl), Rb: H, lower alkylene-Rba or lower alkenylene-Rba where lower alkylene or lower alkenylene specified in Rb can be substituted, Rba: -OR0, -CO2R0, -C(O)N(R0)2, -C(O)N(R0)-S(O)2-(lower alkyl), -C(O)N(R0)-S(O)2-[phenyl, -C(NH2)-NOH, -C(NH2)=NO-C(O)-(lower alkylene)-C(O)R0, -CO2-(lower alkylene)-phenyl, -P(O)(ORp)2, -C(O)R0, -C(O)-phenyl, C3-6cycloalkyl, phenyl or the heterocyclic group where phenyl and the heterocyclic group specified in Rba can be substituted, Rc: H, lower alkylene-OR0, lower alkylene-CO2R0, lower alkylene-P(O)((OPp)2, phenyl where lower alkylene and phenyl are specified in Rd can be substituted, Rd: C1-7-alkyl, lower alkenyl, halogen(lower alkyl), lower alkylene-Rda, lower alkylenylene-Rda, C3-6cycloalkyl, phenyl, naphthyl or the heterocyclic group, where lower alkylene, cycloalkyl, phenyl, naphthyl and the heterocyclic group specified in Rd can be substituted, Rda: -CN, -OR0, -O-(lower alkylene)-CO2R0, -O-naphthyl, -CO2R0, -CO2-(lower alkylene)-N(R0)2, -P(O)(ORp)2, -N(R6)2, -C(O)N(R0)-phenyl, -C(O)N(R0)-(lower alkylene which can be used by -CO2R0)-phenyl, -N(R0)C(O)-phenyl, -N(R0)C(O)-OR0, -N(R0)C(O)-O-(lower alkylene)-phenyl, -N(R0)S(O)2-phenyl, C3-6cycloalkyl, phenyl, naphthyl or the heterocyclic group, where phenyl, naphthyl and heterocyclic group specified in Ra can be substituted, Re: lower alkylene-CO2R0, phenyl, -S(O)2-phenyl or -S(O)2-(heterocyclic group), where phenyl and the heterocyclic group specified in Re can be substituted, X: CH, A: C(R7), R7: -H, or R4 and R7 together can form lower alkylene, where the substituted groups have the substituted specified in cl.1, and provided 7-(cyclohexylamino)-1-ethyl-6-fluor-4-oxo-1,4-dohydroquinoline-3-carbonitryl is excluded. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I) and application of formula (I) for preparing a thrombocyte aggregation inhibitor or a P2Y12 inhibitor.
EFFECT: there are produced new quinol-4-one derivatives showing effective biological properties.
11 cl, 83 tbl, 71 ex
SUBSTANCE: claimed invention relates to medicine, in particular to device for transdermal bisoprolol introduction, which includes base and layer of sensitive to pressure adhesive, which contains bisoprolol, which is layered on one base surface, where maximal value of bisoprolol release in time period immediately from application on skin within 24 hours constitutes 30 mcg/cm2/hour or less; and where velocity of bisoprolol release 24 hours after application on skin constitutes 10 mcg/cm2/hour or less.
EFFECT: device for transdermal introduction reduces skin irritation, especially in case of layering, and can constantly introduce into living organism therapeutically or preventively efficient amount of bioprolol.
5 cl, 3 tbl, 3 dwg, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: what is offered is a coformulated drug for treating various ischemic pathologies containing succinic acid and 2-ethyl-3-(N,N-dimethylcarbamoyloxy)-6-methylpyridine salts with succinic or hydrochloric acid of general formula I where HX is salt-forming succinic or hydrochloric acid, m + 0.1-3.0; showing antihypoxic, antiamnestic and anticonvulsant activity characterised by the fact the relation in I between 2-ethyl-3-(N,N-dimethylcarbamoyloxy)-6-methylpyridine salts and the second component providing a 'synergistic' (potentiating) pharmacological effect by succinic acid makes 1:>0.3. It is shown that succinic acid potentiates declared action of the compound of formula I. It is a reason to create the coformulated drugs exceeding common preparations of 3-oxypyridine groups in pharmacological activity: emoxypin and mexidol, used for treating ischemic pathologies, particularly in diseases accompanied by cerebral ischemia.
EFFECT: preparation of new pharmaceutical compositions for treating ischemic pathologies.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to novel derivatives of diazepane of formula , where A, X, R3, R4, R5, R6, R8, R9, R10, R11, R12, R13, n and m have values, given in description and formula of invention, as well as their physiologically acceptable salts. Said compounds are antagonists of chemokine receptors CCR-2, CCR-5 and/or CCR-3 receptor and can be used in medicine as medications.
EFFECT: obtaining novel diazepane derivatives.
20 cl, 505 ex, 4 tbl
SUBSTANCE: invention refers to medicine, specifically cardiology and concerns treating ischemic heart disease (IHD). For this purpose, the standard integrated drug treatment involving statin is added with administration of the biologically active additive MARISTIM 4.5 mg/day.
EFFECT: method provides higher clinical effectiveness of statins in the given group of patients due to elimination of their inhibitory effect on enzymes of a mitochondrial respiratory chain.
2 cl, 1 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a method of treating hypertension, congestive cardiac failure, stenocardia, myocardial infarction, atherosclerosis, stroke. A method of treating involves introduction to a patient requiring such treatment of the solid oral dosage form containing a therapeutically effective amount of aliskiren or its pharmaceutically acceptable salt in which the active ingredient makes more than 46 wt % of total weight of the oral dosage form. The oral dosage form is presented in the form of a tablet or a film-coated tablet and produced by methods other than wet granulation with excipients by means of water and/or a water solution of a binding agent.
EFFECT: realisation of the specified purpose.
12 cl, 2 ex
SUBSTANCE: invention relates to compounds of general formula where R1 denotes CH3; R2 denotes halogen or CN; R3 denotes H or CH3; R4 denotes H or CH3; n equals 1; and pharmaceutically acceptable salts thereof. The invention also relates to a pharmaceutical composition and use of compounds of formula (I) in preparing a medicinal agent, having CX3CR1 receptor antagonist activity.
EFFECT: compounds can be used as CX3CR1 receptor antagonists.
13 cl, 1 tbl, 10 ex
SUBSTANCE: invention refers to cosmetic compositions for the care of mammal skin and people in particular. The compositions contain a) 1-40 wgh.% of the lipid depot from one or more modified lipids chosen among natural or synthetic lipids, oils, waxes, fatty alcohols, esters of complex fatty acids, glycerides, lecitins, sphingolipids, cholesterins, phospholipids, gangliosides, cerebrosides, ceramides and their mixtures; b) 0.01-12 wgh.% of one or more proteins with the average molecular mass 3500-8000 Da chosen among the proteins of buckwheat, millet, German wheat, tapioca; c) 0.01-10 wgh.% of one or more active agents chosen among the reduced nicotinamide-adenine dinucleotide (NADH), peroxydase, erythorbic acid, glutathione, alpha-liponic acid, green tea extract, cystus tea extract, apple meletin, blackberry extract, elderberry extract or their mixtures; d) 0.1-20 wgh.% one or more adjuvants; e) the rest is water.
EFFECT: invented composition can be used in cosmetic or cosmetic-bineal purposes, in particular, in the liquid, semi liquid or hard form, in the type of emulsion like "oil in the water", "water in the oil", gel emulsion, gel, cream, balsam, lotion, milk, face masks, aerosols, bath and shower additives.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry and medicine, and concerns a composition of solvent ingredients for producing an injection solution, it can be used for preparing injection dosage forms for treating oncological gynaecopathies. The offered agent contains water for injections, low-molecular polyethylene, emulsifier T-2, lutrol F-127, Cremophor RH-40, oil olive in the following proportions, wt %: waters for injections - 1.841; LMPE - 67.114; emulsifier T-2 - 16.778; Lutrol F-127 - 1.677; Cremophor RH-40 - 2.520; oil olive-10.070.
EFFECT: agent exhibits the prolonged effect; it is useable and hygienic.
SUBSTANCE: invention relates to medicine, namely to surgery, and can be used for prevention of postoperative commissural process in abdominal cavity. For this purpose, by the end of operation organs of abdominal cavity are irrigated with perftoran, preliminarily bubbled with ozone-oxygen mixture with specified concentration of ozone 5000 mcg/l. Irrigation is carried out in dose 1 ml/kg of patient's weight. After that, the same amount of ozoned perftoran is introduced intravenously.
EFFECT: invention makes it possible to prevent formation of postoperastive commissures, contributes to early restoration of intestine peristalsis, improvement of tissue oxygenation, makes it possible to reduce terms of antibiotic therapy.
1 ex, 3 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and cosmetology, and represents a bactericidal nail care polish containing a water-soluble film-forming hydroxyalkyl chitosan or carboxyalkyl chitosan material, a bactericidal agent, a polar aqueous-alcoholic solvent which as the bactericidal agent contain bentonite powders nanostructured to particle size 150 nm and less, and intercalated by metal ions Ag+ or Ag+ and Zn2+, or Cu2+ and Zn2+, or Ag+ and Cu2+ and Zn2+ which are introduced into a prepared emulsion of the film-forming material in the form of 4-10 % hydrosol; the components of the composition are taken in certain proportions, wt %, and the weight ratio parts of the mixtures of bentonite powders intercalated by metal ions is: for metal ions Ag+ and Zn2+ (1:(0.5÷1)); for metal ions Cu2+ and Zn2+ (1÷0.5):(0.5÷1); for metal ions Ag+ and Cu2+ and Zn2+ 1:(0.5):(0÷1).
EFFECT: invention provides extended range of polishes, reduced risks of negative dermatological manifestations, effective bactericidal protection.
6 cl, 8 ex, 2 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to food and chemical-pharmaceutical industry, namely to creation of a concentrated oil/water emulsion of replacement fat of zero caloric content intended for both appetite control and management, and weight regulation. A composition for appetite control and management, and weight regulation, represents the concentrated emulsion containing replacement fat with zero caloric content selected from a group of saccharose polyesters consisting generally of mixed saccharose octa-, hepta- and hexaesters, triglycerides of caprylic/capric fatty acids, edible Vaseline oil, an emulsifying stabiliser selected from the group: gum arabic, saponin, modified starch, a flavour additive, a preservative, vitamin A, beta carotene and water taken in certain proportions.
EFFECT: received composition shows high functional activity of the developed concentrated emulsions in the prescribed sparing mode of therapy "ГЛ".
3 cl, 1 tbl
SUBSTANCE: invention refers to production of a drug preparation in the form of a fluid mixture of glass particles containing drugs and a fluid medium. A creamy or pasty consistence of the fluid mixture is formed by adding a small amount of the liquid to particles. The mixture does not contain an excess amount of the liquid, therefore the mixture is not exfoliated.
EFFECT: provided wide range of liquid carriers accessible in preparations of this type.
3 cl, 3 dwg
SUBSTANCE: invention relates to method of water-in-oil and oil-in-water nanoemulsions preparation, where a disperse phase is distributed in a disperse phase in the form of drops with diameter from 1 to 500 nm, which includes the following stages: 1) preparation of homogeneous water/oil mixture (1) characterised by surface tension of less than 1 mN/m, including water in amount from 30 to 70 wt %, at least two surfactants with different HLB selected from nonionic, anionic, polymer surfactants, besides, the specified surfactants are present in an amount to make the mixture homogeneous; 2) dissolution of the mixture (1) in the disperse phase, made of oil or water with addition of a surfactant selected from nonionic, anionic, polymer surfactants, besides, amount of the disperse phase and the surfactant is such that a nanoemulsion is produced with HLB differing from the HLB of the mixture (1). Invention also relates to water-in-oil nanoemulsions produced by this method with value of HLB from 6 to 14 and containing water in the amount from 1 to 30%, total amount of surfactants is from 0.1 to 20%, besides, the remaining amount (up to 100%) makes oil or oil in water, having the value of HLB that is more than 10, and containing oil in amount from 1 to 30%, total amount of surfactants is from 0.1 to 20%, and the remaining amount (up 100%) is water. The invention also relates to application of these nanoemulsions as carriers of additives in food, oil, cosmetic, pharmaceutical industries and in fuel sector.
EFFECT: method ensures production of water-in-oil or oil-in-water nanoemulsions with high stability, a more simple and a wider area of application.
33 cl, 26 ex
SUBSTANCE: invention relates to a chrysophanol conjugate or its derivative, characterised by general formula (I), in which R1-R8 is a group selected from -H, -OH, -OCH3, -CH3, provided that not less than two groups from R1-R8 denote -H or provided that one or two of groups R2, R3, R6 and R7 are a -COOH group, M is a nitrogen organic base selected from a group comprising chitosamin, glucosamin, or a basic amino acid selected from a group comprising arginine, lysine, carnitine, and group M is bonded to the chrysophanol part in the conjugate.
EFFECT: invention relates to use of the conjugate as a medicinal agent for preventing or treating diabetic nephropathy, osteoarthritis, rheumatic or rheumatoid arthritis, intestinal adhesion, intestinal peristalsis restoration, and a medicinal agent based on the conjugate.
8 cl, 4 dwg, 57 ex, 18 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to chemical-pharmaceutical industry and deals with elaboration of method of obtaining blood-substituting composition on two high pressure desintegrators from the mixture of two perfluorocarbons, quickly excreted (C8-C10) and(or) slowly excreted (C11-C12), is emulsified with proxalon-268 from 0.2% to 20% with molecular weight 6-12 thousand Da, with further addition of acceptable electrolyte solution, with formation of fine dispersion emulsion with the average particle size 30-120 nm. Method is realised by homogenisation of obtained mixture on two high pressure homogenisers with two or four extrusion devices of homogenisers.
EFFECT: method makes it possible to obtain highly stable perfluorocarbonic emulsions, which possess lower reactogenicity.
12 cl, 6 ex, 1 tbl, 1 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical and cosmetic industry, and concerns development of a new safe and nontoxic composition of perfluorocarbon emulsion with colloidal silver, to ensure new, intensified properties for effective medicobiological and cosmetic application. Substance of the invention consists in development of a composition of perfluorodcalin (PFD) or perfluorotributylamine (PFTBA), or perfluoroctylbromide (PFOB), or perfluoromethylcyclohexyl-piperidine (PFMCP), proxanol, sodium chloride and colloidal silver; or mixed PFD/PFMCP, or PFD/PFTBA, or PFOB/PFTBA, or PFOB/PFMCP, proxanol, sodium chloride and colloidal silver; or mixed PFOB/PFD/PFMCP or PFOB/PFD/PFTBA, proxanol, sodium chloride and colloidal silver; or mixed PFOB/PFD/PFMCP/PFTBA, proxanol, sodium chloride and colloidal silver. The concentration of colloidal silver in the perfluorocarbon composition makes 0.00006-0.6 wt %.
EFFECT: composition exhibits high efficacy and stability.
17 cl, 12 ex
SUBSTANCE: invention relates to novel chemical compounds and can be used in medicine, particularly radiology as an X-ray contrast agent during X-ray examination of various organs. The invention discloses a composite tantalate of rare-earth elements with the formula M1-xM'xTaO4, where 0.01≤x≤0.45; M and M' are elements selected from a group consisting of: yttrium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, as a contrast agent for X-ray diagnosis. The disclosed contrast agent, which provides a high level of X-ray absorption, enables to smoothly and continuously vary the level of absorption with the same quantitative content of the agent owing to change in values of x, i.e., owing to change in the ratio of atoms the first and second elements in the crystal lattice of tantalate.
EFFECT: contrast agent broadens the possibility of reliable diagnosis of cavernous organs.